GO:0019371 cyclooxygenase pathway: Prostaglandin Biosynthesis, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0019371 (cyclooxygenase pathway) describes the biochemical route that converts arachidonic acid into prostaglandin-endoperoxides PGG2 and PGH2, with prostaglandin-endoperoxide synthase (cyclooxygenase) catalyzing the committed step.
• The pathway is initiated by phospholipase A2-mediated release of arachidonic acid and proceeds through COX-1 (PTGS1) and COX-2 (PTGS2), which are the central enzymes of this GO term.
• Downstream prostaglandin synthases convert PGH2 into bioactive prostaglandins such as PGE2, PGD2, PGF2alpha, PGI2 and thromboxane A2, which act in inflammation, immunity, development and vascular biology [2,7,8].
• Cyclooxygenase pathway activity shapes tumor immunity and tumor growth, and COX-dependent prostaglandins can promote immune evasion.
• The pathway is essential in vertebrate embryonic development, and its spatiotemporal expression is tightly regulated [3,5].
• Nonsteroidal anti-inflammatory drugs (NSAIDs) target cyclooxygenases, making this pathway a major pharmacological and research focus [3,8].
Description
The cyclooxygenase pathway (GO:0019371) is the metabolic route by which arachidonic acid is converted into prostaglandin-endoperoxides and subsequently into bioactive prostaglandins. In this pathway, prostaglandin-endoperoxide synthase, commonly known as cyclooxygenase (COX), catalyzes the committed step that transforms arachidonic acid into the prostaglandin-endoperoxides PGG2 and PGH2. Because this step is rate-limiting and irreversible, the cyclooxygenase enzymes PTGS1 (COX-1) and PTGS2 (COX-2) are considered the central regulators of prostaglandin synthesis [2,8]. The pathway is not a single reaction but a coordinated cascade involving phospholipases, cyclooxygenases and terminal prostaglandin synthases. Researchers study GO:0019371 because its products influence inflammation, immune surveillance, cardiovascular homeostasis and embryonic development, and because pharmacological inhibition of cyclooxygenases has broad clinical consequences [1,3,8]. Dysregulated cyclooxygenase pathway activity has been linked to cancer progression and immune evasion, making it a target for mechanistic and therapeutic studies. In parallel, the pathway is required for normal developmental processes, and disruption of its enzymes can alter embryonic patterning [3,5].
cyclooxygenase pathway At A Glance
| GO ID | GO:0019371 |
|---|---|
| GO term | cyclooxygenase pathway |
| Ontology | biological_process |
| Synonym | None listed in QuickGO |
| Major function | Conversion of arachidonic acid to prostaglandin-endoperoxides PGG2 and PGH2 and subsequent prostaglandin formation |
| Committed step | Catalyzed by prostaglandin-endoperoxide synthase (cyclooxygenase) |
| Key enzymes | PTGS1 (COX-1), PTGS2 (COX-2) |
| Substrate | Arachidonic acid |
| Key products | PGG2, PGH2 and downstream prostaglandins |
What Is GO:0019371?
GO:0019371 (cyclooxygenase pathway) is defined as the chemical reactions and pathways by which prostaglandins are formed from arachidonic acid, and in which prostaglandin-endoperoxide synthase (cyclooxygenase) catalyzes the committed step in the conversion of arachidonic acid to the prostaglandin-endoperoxides PGG2 and PGH2. In practical terms, this GO term covers the enzymatic cascade that begins with arachidonic acid release and proceeds through cyclooxygenase-mediated oxygenation and cyclization to generate PGG2 and PGH2, which are then converted by downstream synthases into prostaglandins and related eicosanoids.
Why Is cyclooxygenase pathway Important in Cell Biology?
The cyclooxygenase pathway is important because it generates prostaglandins that control inflammation, immunity, vascular tone and developmental programs, and because its central enzymes are the targets of widely used NSAIDs [2,3,8]. Experimental evidence shows that cyclooxygenase-dependent prostaglandin production can promote tumor growth by enabling evasion of immune destruction, linking this pathway directly to cancer biology. At the same time, the pathway is required for normal vertebrate embryonic development, and its enzymes display tightly regulated spatiotemporal expression patterns [3,5]. These dual roles in physiology and disease make GO:0019371 a recurring focus in inflammation, oncology, cardiovascular and developmental research [1,4,8].
• Controls production of prostaglandins that mediate inflammation and pain.
• Supports tumor growth through cyclooxygenase-dependent evasion of immunity.
• Is required for normal vertebrate embryonic development [3,5].
• Is the pharmacological target of nonsteroidal anti-inflammatory drugs [3,8].
• Regulates cardiovascular function through prostaglandin and thromboxane products.
• Interacts reciprocally with nitric oxide signaling in pathophysiology.
• Contributes to liver disease biology through the COX-2/prostanoid pathway.
• Is studied in lung cancer and other malignancies as a therapeutic axis.
• Provides a model cascade for studying eicosanoid metabolism.
• Offers multiple nodes for CRISPR-based functional dissection.
What Happens During cyclooxygenase pathway?
Release of arachidonic acid
In simple terms: First, the building block arachidonic acid is freed from membrane lipids.
The cyclooxygenase pathway begins with the availability of arachidonic acid, which is typically liberated from membrane phospholipids by phospholipase enzymes. This release step provides the substrate pool that feeds the subsequent cyclooxygenase reactions and is a prerequisite for prostaglandin formation.
Cyclooxygenase committed step
In simple terms: The COX enzymes then convert arachidonic acid into short-lived intermediates.
Prostaglandin-endoperoxide synthase (cyclooxygenase) catalyzes the committed step of the pathway, converting arachidonic acid into the prostaglandin-endoperoxides PGG2 and PGH2. This reaction is the defining feature of GO:0019371 and is carried out by the COX-1 (PTGS1) and COX-2 (PTGS2) enzymes [2,8].
Downstream prostaglandin synthesis
In simple terms: Specialized enzymes then turn the intermediate into different prostaglandins.
PGH2 serves as a common precursor that is converted by terminal prostaglandin synthases into bioactive products such as PGE2, PGD2, PGF2alpha, PGI2 and thromboxane A2. These products act through specific receptors to mediate diverse physiological and pathological effects [2,7].
Integration with immunity and inflammation
In simple terms: The prostaglandins made here shape how the immune system behaves.
Cyclooxygenase-dependent prostaglandins influence immune responses, and experimental work has shown that tumor growth can occur through evasion of immunity in a cyclooxygenase-dependent manner. This links the pathway to inflammatory and immune regulatory networks [1,7].
Developmental roles
In simple terms: The same pathway is also active during embryo formation.
Cyclooxygenase pathway enzymes are expressed in spatiotemporal patterns during vertebrate embryonic development, and NSAID exposure has implications for developmental processes [3,5]. This indicates that the pathway is not only a mediator of adult inflammation but also a developmental regulator [3,5].
Key Genes Involved in GO:0019371 cyclooxygenase pathway
The cyclooxygenase pathway involves arachidonic acid release, cyclooxygenase catalysis and terminal prostaglandin synthesis, and the following genes and proteins are central to its function and regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PTGS1 | Constitutive cyclooxygenase (COX-1) catalyzing the committed step | Studied for housekeeping prostaglandin synthesis and NSAID effects [2,8] |
| PTGS2 | Inducible cyclooxygenase (COX-2) catalyzing the committed step | Central to inflammation, cancer and immune evasion research [1,2] |
| PLA2G4A | Phospholipase A2 releasing arachidonic acid | Upstream regulator of substrate availability |
| PTGES | Terminal synthase producing PGE2 | Linked to prostaglandin E2 biology in disease |
| PTGDS | Terminal synthase producing PGD2 | Studied in allergic and immune responses |
| PTGIS | Terminal synthase producing PGI2 (prostacyclin) | Relevant to vascular biology [2,8] |
| TBXAS1 | Terminal synthase producing thromboxane A2 | Relevant to platelet and cardiovascular function [2,8] |
| HPGDS | Hematopoietic prostaglandin D synthase | Studied in immune and inflammatory settings |
| AKR1C3 | Prostaglandin reductase family member | Modulates prostaglandin levels |
| CBR1 | Carbonyl reductase contributing to prostaglandin metabolism | Affects prostaglandin turnover |
| PTGER1 | Prostaglandin E2 receptor EP1 | Mediates downstream signaling |
| PTGER2 | Prostaglandin E2 receptor EP2 | Mediates downstream signaling |
| PTGER4 | Prostaglandin E2 receptor EP4 | Linked to immune modulation [1,2] |
| PTGIR | Prostacyclin receptor | Relevant to vascular effects [2,8] |
| TBXA2R | Thromboxane A2 receptor | Relevant to cardiovascular biology [2,8] |
| NOS2 | Nitric oxide synthase reciprocally regulated with cyclooxygenase | Studied in pathophysiology interactions |
| NFKB1 | Transcription factor influencing COX-2 expression | Relevant to inflammatory regulation |
How Is cyclooxygenase pathway Regulated?
Cyclooxygenase pathway activity is regulated at multiple levels, including substrate release by phospholipases, differential expression of PTGS1 and PTGS2, and downstream prostaglandin synthase availability. Reciprocal regulation between the nitric oxide pathway and the cyclooxygenase pathway has been described in pathophysiology, indicating crosstalk between these signaling systems. In disease contexts such as liver disease, COX-2/prostanoid signaling is modulated and contributes to pathology. Cardiovascular biology also reflects regulation of cyclooxygenases and their products, which affects vascular homeostasis.
cyclooxygenase pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PTGS2 | Tumor immune evasion and cancer growth | Knockout or overexpression in tumor cell lines |
| PTGS2 | Liver disease | Knockout in hepatocyte models |
| PTGS1/PTGS2 | Cardiovascular effects of COX inhibition | Knockout and point-mutation models |
| PTGS1/PTGS2 | Embryonic developmental roles | Developmental knockout models [3,5] |
| NOS2 | Reciprocal regulation with cyclooxygenase in pathophysiology | Knockout and overexpression models |
Cancer and immune evasion
Cyclooxygenase-dependent prostaglandin production can support tumor growth by enabling evasion of immunity, and COX-2 inhibitors have been explored in lung cancer [1,6]. These findings place GO:0019371 at the interface of inflammation and tumor immunology [1,6].
Cardiovascular disease
Cyclooxygenases and their prostaglandin products influence cardiovascular function, and pharmacological modulation of this pathway has cardiovascular implications. The balance between prostacyclin and thromboxane is particularly relevant to vascular biology [2,8].
Liver disease
The COX-2/prostanoid pathway has been implicated in liver diseases, where prostaglandin signaling contributes to hepatic pathology. This makes the pathway a subject of hepatology research.
Embryonic development and NSAID exposure
NSAIDs and cyclooxygenase pathway enzymes have implications for embryonic development, and spatiotemporal characterization of pathway enzymes during vertebrate development has been reported [3,5]. This highlights developmental toxicity considerations for COX-targeting drugs [3,5].
From cyclooxygenase pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PTGS2 alter prostaglandin production? | PTGS2 knockout cell line |
| Does a catalytic residue mutation abolish cyclooxygenase activity? | Point-mutation knock-in of PTGS2 |
| Can tagged COX-2 be used for localization studies? | Tagged knock-in of PTGS2 |
| Does overexpression of PTGS2 drive prostaglandin-dependent phenotypes? | PTGS2 overexpression model |
| Does loss of a terminal prostaglandin synthase shift product profiles? | Knockout of PTGES or PTGIS |
| Can pathway genes be screened for functional interactions? | CRISPR library screening |
How to Study the cyclooxygenase pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcript levels of pathway genes | Expression profiling |
| qPCR | Specific gene expression | Validation of PTGS1/PTGS2 changes |
| Lipidomics / mass spectrometry | Prostaglandin products | Pathway output measurement |
| Immunofluorescence | Protein localization | Developmental spatiotemporal studies |
| CRISPR knockout | Loss-of-function effects | Causal gene testing |
| CRISPR point mutation | Catalytic or regulatory residue function | Mechanistic dissection |
| Tagged knock-in | Protein tracking and interaction | Localization and complex analysis |
| CRISPR library screening | Pathway-wide genetic interactions | Discovery of modifiers |
Gene expression analysis
RNA-seq and qPCR can quantify expression of PTGS1, PTGS2 and downstream synthases across conditions, helping to define pathway activity states [2,4].
Prostaglandin profiling
Mass spectrometry-based lipidomics can measure prostaglandin products such as PGE2 and PGH2-derived metabolites to assess pathway output.
Protein localization and imaging
Tagged knock-in and immunofluorescence approaches allow spatiotemporal characterization of cyclooxygenase pathway enzymes during development and in tissues.
Functional perturbation
CRISPR knockout, point mutation and overexpression models can test causality of specific pathway genes in inflammation, immunity and development [1,3,5].
How CRISPR Can Be Used to Study GO:0019371 cyclooxygenase pathway
Knockout
CRISPR knockout of PTGS1, PTGS2 or terminal synthases can eliminate specific steps of the cyclooxygenase pathway and reveal their contributions to prostaglandin production and disease phenotypes [1,2].
Point Mutation
Point mutations can be introduced into catalytic or regulatory residues of cyclooxygenase enzymes to test which amino acids are required for the committed step and for downstream signaling [2,8].
Knock-in
Tagged knock-in of pathway genes enables tracking of enzyme localization and interaction, which is useful for spatiotemporal studies during development.
Overexpression
Overexpression of PTGS2 or downstream synthases can amplify pathway output and model disease states such as chronic inflammation or tumor-associated prostaglandin production [1,4].
How EDITGENE Supports cyclooxygenase pathway Research
Researchers studying cyclooxygenase pathway-related genes often need to determine whether a candidate gene is causally involved in prostaglandin production, inflammation, immunity or development. EDITGENE provides CRISPR-based cell models and screening services to support such mechanistic studies.
Contact EDITGENE today to design your custom CRISPR model for cyclooxygenase pathway research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PTGS2 Knockout HEK293 Cell Line | EDJ-KQ586 | Human | 5743 | Details Get a Quote |
| CTHRC1 Knockout HEK293 Cell Line | EDJ-KQ2649 | Human | 115908 | Details Get a Quote |
| PTGES Knockout HEK293 Cell Line | EDJ-KQ3248 | Human | 9536 | Details Get a Quote |
| PTGDS Knockout HEK293 Cell Line | EDJ-KQ5581 | Human | 5730 | Details Get a Quote |
| PTGS1 Knockout HEK293 Cell Line | EDJ-KQ5584 | Human | 5742 | Details Get a Quote |
| PTGIS Knockout HEK293 Cell Line | EDJ-KQ5586 | Human | 5740 | Details Get a Quote |
| HPGDS Knockout HEK293 Cell Line | EDJ-KQ8757 | Human | 27306 | Details Get a Quote |
| PRXL2B Knockout HEK293 Cell Line | EDJ-KQ9028 | Human | 127281 | Details Get a Quote |
| PTGES2 Knockout HEK293 Cell Line | EDJ-KQ9461 | Human | 80142 | Details Get a Quote |
| SIGMAR1 Knockout HEK293 Cell Line | EDJ-KQ15261 | Human | 10280 | Details Get a Quote |
| PTGS2 Knockout HeLa Cell Line | EDJ-KQ18034 | Human | 5743 | Details Get a Quote |
| SIGMAR1 Knockout A-549 Cell Line | EDJ-KQ18095 | Human | 10280 | Details Get a Quote |
| PTGS2 Knockout A-549 Cell Line | EDJ-KQ19007 | Human | 5743 | Details Get a Quote |
| PTGES2 Knockout HCT 116 Cell Line | EDJ-KQ36159 | Human | 80142 | Details Get a Quote |
| PTGES2 Knockout HeLa Cell Line | EDJ-KQ36160 | Human | 80142 | Details Get a Quote |
Displaying Records 1 To 15 Of 46 Records
- 1
- 2
- Next Page »
Frequently Asked Questions About cyclooxygenase pathway
What is the cyclooxygenase pathway?
The cyclooxygenase pathway (GO:0019371) is the set of reactions that convert arachidonic acid into prostaglandin-endoperoxides PGG2 and PGH2 and then into prostaglandins, with cyclooxygenase catalyzing the committed step.
What genes are involved in the cyclooxygenase pathway?
Key genes include PTGS1 and PTGS2, which encode the cyclooxygenase enzymes, as well as phospholipases and terminal prostaglandin synthases such as PTGES and PTGIS.
What does GO:0019371 mean?
GO:0019371 is the Gene Ontology identifier for the biological process cyclooxygenase pathway, defined by the conversion of arachidonic acid to prostaglandin-endoperoxides and prostaglandins.
Why is the cyclooxygenase pathway important in cancer?
Cyclooxygenase-dependent prostaglandin production can promote tumor growth through evasion of immunity, and COX-2 inhibitors have been studied in lung cancer [1,6].
How is the cyclooxygenase pathway regulated?
It is regulated by substrate release, differential expression of PTGS1 and PTGS2, downstream synthase availability and crosstalk with nitric oxide signaling [2,7].
What drugs target the cyclooxygenase pathway?
Nonsteroidal anti-inflammatory drugs target cyclooxygenases, and their implications for embryonic development and cardiovascular biology have been reviewed [3,8].
What is the role of COX-2 in liver disease?
The COX-2/prostanoid pathway has been implicated in liver diseases and contributes to hepatic pathology.
How can CRISPR be used to study the cyclooxygenase pathway?
CRISPR knockout, point mutation, knock-in and overexpression can be used to test the function of PTGS1, PTGS2 and downstream pathway genes [1,2,5].
What methods measure cyclooxygenase pathway activity?
RNA-seq, qPCR, lipidomics and immunofluorescence are commonly used to measure expression, products and localization of pathway components [2,5].
Is the cyclooxygenase pathway important in development?
Yes, cyclooxygenase pathway enzymes show spatiotemporal expression during vertebrate embryonic development, and NSAID exposure has developmental implications [3,5].
Conclusion
GO:0019371 (cyclooxygenase pathway) defines the core biochemical route from arachidonic acid to prostaglandin-endoperoxides and prostaglandins, with cyclooxygenase enzymes catalyzing the committed step. Its products influence inflammation, immunity, cardiovascular function and development, and the pathway is a major pharmacological target [1,3,8]. CRISPR-based models and functional screening provide powerful tools to dissect the causal roles of pathway genes in health and disease [1,2,5].
References
- 1. Zelenay S et al.. 2015. Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity.. Cell 162(6):1257-70 PMID: 26343581
- 2. Wang B et al.. 2021. Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets.. Signal Transduct Target Ther 6(1):94 PMID: 33637672
- 3. Leathers TA et al.. 2023. Nonsteroidal anti-inflammatory drugs and implications for the cyclooxygenase pathway in embryonic development.. Am J Physiol Cell Physiol 324(2):C532-C539 PMID: 36622071
- 4. Hu KQ. 2003. Cyclooxygenase 2 (COX2)-prostanoid pathway and liver diseases.. Prostaglandins Leukot Essent Fatty Acids 69(5):329-37 PMID: 14580367
- 5. Leathers TA et al.. 2025. Spatiotemporal characterization of cyclooxygenase pathway enzymes during vertebrate embryonic development.. Dev Biol 518:61-70 PMID: 39581452
- 6. Ramalingam S et al.. 2004. Cyclooxygenase-2 inhibitors in lung cancer.. Clin Lung Cancer 5(4):245-53 PMID: 14967078
- 7. Salvemini D et al.. 2013. Reciprocal regulation of the nitric oxide and cyclooxygenase pathway in pathophysiology: relevance and clinical implications.. Am J Physiol Regul Integr Comp Physiol 304(7):R473-87 PMID: 23389111
- 8. Mitchell JA et al.. 2021. Cyclooxygenases and the cardiovascular system.. Pharmacol Ther 217:107624 PMID: 32640277
